Table 3.

Summary of genomics and miRNA studies in MF/SS

Authors	Platform	Cells	Findings
Mao et al (2003)	Genomic microarray	MF/SS	RAF1 (3p25), CTSB (8p22),PAK1 (11q13) JUNB (19p13) increased in MF. FGFR1 (8p11), PTPN1 (20q13) and BCR (22q11) in SS
Van Doorn et al (2005)	Epigenetic CGH	MF/SS	BCL2 hypermethylated, TP73 (p73), CDKN2A (p16), CDKN2B (p15), CHFR, ACS (TMS1) methylated
Vermeer et al (2008)	CGH	SS	Gain of MYC, STAT3. Loss of MYC antagonist MXI1 and MNT, ZEB1, DUSP5.
Caprini et al (2009)	CGH, SNP	SS	Loss 17, BAG4, BTRC, NKIRAS2, PSMD3, TRAF2
Van Doorn et al (2009)	Array CGH	MF skin	Gain 7q36, 7q21, loss 5q13, 9p21, FASTK and SKAP1 gained. MF differs from SS in chromosomal alteration. 9p21, 8q24, 1q21 associated with poor prognosis.
Laharanne et al (2010)	CGH	MF/SS	MF-Gain 1q 7p or 7q. Loss 9p21. SS show 8q and 17q gain. 10p and 17p losses.
Ballabio et al (2010)	MicroRNA array	SS	Most MIR decreased. 10 MIR discriminatory. Increased-MIR145, MIR574, MIR200, MIR199A, MIR143. Decreased MIR223, MIR342, MIR150, MIR24-1, MIR186
Narducci et al (2011)	MicroRNA array	SS	MIR21, MIR486 and MIR214 upregulated in SS
Van Kester et al (2011)	MicroRNA array	MF	MIR155 and MIR92A increased in tumour. MIR93 highest. Different from MIR in SS.

SS, Sezary Syndrome; MF, Mycosis Fungoides; CGH, comparative genomic hybridization; SNP, single nucleotide polymorphism